Pembrolizumab reduces recurrence risk in stage II melanoma
Crossref DOI link: https://doi.org/10.1038/s41571-022-00638-w
Published Online: 2022-04-19
Published Print: 2022-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Killock, David
Text and Data Mining valid from 2022-04-19
Version of Record valid from 2022-04-19
Article History
First Online: 19 April 2022